NMN

NMN, short for nicotinamide mononucleotide, is a naturally occurring molecule the body uses as a direct building block to make NAD+, a coenzyme every cell needs for energy production and dozens of other processes. NAD+ levels decline with age, which has made NMN one of the most widely sold longevity supplements. It has real published human clinical trials behind it, more than many longevity compounds, but there is still no single agreed-upon effective human dose, and its regulatory status as a U.S. dietary supplement has shifted more than once.

Research snapshot

Peptide category	Small-molecule nucleotide (not a peptide); naturally occurring NAD+ precursor
Primary research interest	Longevity/healthy aging support via raising NAD+ levels
Highest available evidence	Tier 1/2 — has real published human clinical trials, more than many longevity compounds, but no single agreed-upon effective human dose
Human research available	Yes, multiple published human clinical trials
Development status	Marketed as a dietary supplement; also separately pursued as an investigational pharmaceutical by at least one company
Regulatory status	Not FDA-approved as a drug for any indication. US dietary-supplement status shifted: excluded in 2022 after IND authorization for a pharmaceutical candidate, then restored specifically for beta-NMN as of 2025

Technical identity

Primary name	Nicotinamide mononucleotide (NMN)
Alternative names	Beta-NMN (β-NMN)
Peptide sequence	Not applicable — this is a small-molecule nucleotide, not a peptide
Amino-acid length	Not applicable — this is a small-molecule nucleotide, not a peptide
Molecular formula	C11H15N2O8P
Molecular weight	Approximately 334.22 g/mol
CAS Registry Number	1094-61-7
PubChem CID	14180
Peptide class	Not applicable — nucleotide (NAD+ precursor)
Primary biological target	Converted by NMNAT enzymes into NAD+, a coenzyme central to cellular energy metabolism and sirtuin/PARP signaling
Developer or originator	Naturally occurring metabolite; found in small amounts in foods such as broccoli, avocado, and edamame, and produced endogenously
Development status	Widely sold as a dietary supplement; separately in pharmaceutical investigation by at least one company

What it is

Nicotinamide mononucleotide (NMN) is a naturally occurring nucleotide found in small amounts in foods such as broccoli, avocado, and edamame, and produced continuously inside the human body as part of normal NAD+ metabolism. It is one step away, chemically, from NAD+ (nicotinamide adenine dinucleotide) itself; the enzyme nicotinamide mononucleotide adenylyltransferase converts NMN into NAD+ inside cells.

Interest in NMN grew out of decades of research into NAD+, a coenzyme essential for cellular energy metabolism and for the activity of sirtuins (a family of proteins linked to cellular stress resistance) and PARP enzymes (involved in DNA repair). NAD+ levels measurably decline with age in humans and animals, and researchers, most prominently David Sinclair’s laboratory at Harvard, have studied whether restoring NAD+ via precursor molecules like NMN or the related compound nicotinamide riboside (NR) could counteract aspects of aging. NMN itself is not a novel synthetic invention; it is naturally present in the body, and supplement manufacturers sell a synthesized version as an oral capsule, sublingual tablet, or powder.

NMN’s regulatory path in the United States has been unusually turbulent for a supplement ingredient: the FDA determined in 2022 that NMN could not be marketed as a dietary supplement because it had been authorized for investigation as a new drug (related to a pharmaceutical company’s IND filing), a decision that was later reversed specifically for beta-NMN, restoring its lawful dietary-supplement status as of 2025. This regulatory back-and-forth is itself part of NMN’s story and is distinct from questions about its actual efficacy.

How does it work?

Plain-English explanation

Every cell needs a molecule called NAD+ to convert food into usable energy and to run repair and maintenance processes, but the amount of NAD+ your cells can make and hold onto declines as you get older. NMN is a direct precursor, essentially a raw ingredient, that cells use to build more NAD+. The idea behind NMN supplementation is that giving the body extra raw material might help offset the age-related decline in NAD+ and, in turn, support energy metabolism and cellular repair processes that depend on it.

Technical explanation

NMN is converted to NAD+ via the enzyme nicotinamide mononucleotide adenyltransferase (NMNAT), bypassing part of the salvage pathway that also involves nicotinamide riboside kinase when NR is the starting precursor instead. NAD+ serves as an essential cofactor for redox reactions throughout cellular metabolism and as a required substrate for sirtuin enzymes (SIRT1 through SIRT7, implicated in mitochondrial biogenesis, inflammation regulation, and cellular stress resistance) and for PARP enzymes involved in DNA damage repair, as well as for CD38, an NAD+-consuming enzyme whose activity also increases with age and is thought to contribute to age-related NAD+ decline. Oral NMN’s bioavailability and precise absorption mechanism in humans, including whether intact NMN is absorbed directly or broken down and reassembled from smaller components before entering cells, remains an active area of research rather than a settled matter.

Potential benefits and research applications

Insulin sensitivity in prediabetic women

What is being investigated: whether NMN supplementation improves insulin sensitivity in women with prediabetes. How the effect might occur: by restoring NAD+ levels that support metabolic function in muscle tissue. Evidence: a randomized, placebo-controlled human trial published in Science in 2021 (Yoshino et al., Washington University) reported that NMN supplementation improved muscle insulin sensitivity and some aspects of insulin signaling in postmenopausal women with prediabetes over a 10-week period. Strength: has been shown in at least one adequately controlled human clinical trial in this specific population. Limitation: this was a modest-sized trial in a specific population (postmenopausal prediabetic women); it does not establish the same effect in men, younger adults, or people without prediabetes.

Exercise performance and aerobic capacity

What is being investigated: whether NMN improves aerobic endurance or exercise performance. How the effect might occur: via improved mitochondrial energy metabolism supporting muscle performance during exercise. Evidence: a published human study in amateur runners reported improved aerobic capacity measures with NMN supplementation over several weeks. Strength: published human research, though from a relatively small trial in a specific athletic population. Limitation: results in trained or elite athletes, and in sedentary or older populations, may differ, and this remains a limited evidence base compared to a robust, replicated trial program.

General functional and mobility measures in older or unwell adults

What is being investigated: whether NMN supplementation improves functional measures such as walking distance and general health assessments. How the effect might occur: through broad support of cellular energy metabolism as NAD+ levels are restored. Evidence: a published clinical trial reported improvement in six-minute walking test distance and general health assessment scores with NMN supplementation. Strength: published human clinical trial evidence, though the size, population, and duration of such trials vary and results have not been consistently replicated across a large, definitive trial program. Limitation: functional improvement in a walking test does not by itself establish a broader anti-aging or longevity effect.

Longevity and healthspan extension (the core claim)

What is being investigated: whether restoring NAD+ via NMN supplementation extends lifespan or meaningfully slows biological aging in humans. How the effect might occur: through sirtuin activation, improved mitochondrial function, and enhanced DNA repair capacity, mechanisms demonstrated in animal studies. Evidence: long-term NMN administration has been shown to mitigate age-associated physiological decline in mouse studies (improved metabolic parameters, some functional measures) at doses far higher, relative to body weight, than typical human supplement doses. Strength: is being investigated for in humans but has not been established as a proven lifespan-extension or healthspan intervention; the strongest longevity-specific evidence remains in mice, not people. Limitation: no human trial has run long enough, or measured hard outcomes (like mortality or major disease incidence) sufficient, to confirm a longevity effect in people.

What dosage information circulates?

Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.

Amounts studied in human research

An early Japanese safety study (Keio University) reported that a single oral dose of up to 500 milligrams of NMN was safe and well tolerated in healthy men, without evaluating efficacy (evidence category: published human clinical trial, safety-focused). The 2021 Science trial in prediabetic women used daily oral NMN over 10 weeks; the specific milligram dose used in that trial is reported in the original publication rather than consistently restated with full precision across secondary sources, and readers should consult the primary Yoshino et al. 2021 paper for the exact protocol dose. Other published human trials investigating exercise performance and functional outcomes have generally used daily oral doses in the range of a few hundred milligrams to around 1,250 milligrams per day over periods of several weeks to a few months, though exact amounts, durations, and populations vary meaningfully between individual trials and are not standardized into one agreed protocol (evidence category: published human clinical trial, multiple distinct studies).

Amounts studied in animal research

Long-term mouse studies of NMN supplementation, including foundational work from the Sinclair and Imai laboratories, have commonly used doses in the range of roughly 100 to 500 milligrams per kilogram of body weight per day, administered orally (often in drinking water) over periods ranging from several weeks to essentially the animals’ remaining lifespan, and have reported improvements in various age-associated physiological measures (evidence category: published animal research). These doses, scaled to body weight, are substantially higher on a per-kilogram basis than typical human supplement doses, and direct mouse-to-human dose conversion is not straightforward or well validated for NMN specifically.

Practitioner and community-reported protocols

NMN supplement vendors and longevity forums commonly recommend oral daily doses in the range of roughly 250 to 1,000 milligrams per day, sometimes divided into two doses, often taken in the morning based on a theoretical (not clinically established) connection to circadian NAD+ metabolism. These figures loosely track the range used in some published human trials but are also widely repeated across vendor marketing pages as a generic “recommended dose” without each specific vendor tracing its figure to a particular study (evidence category: vendor/community reported, with the general dose range overlapping published research but the specific vendor-recommended figures not individually sourced). Widely repeated online, but the specific “optimal” dose promoted by many vendors could not be traced to one consistent original source beyond general overlap with the published trial range.

Side effects, risks, and limitations

Published human trials of NMN, including the Keio University safety study and subsequent efficacy trials, have generally reported it as well tolerated at the doses tested, with no serious adverse events consistently reported in the short-to-medium-term trials published to date. However, broader long-term safety data in large, diverse human populations over years of continuous use does not yet exist. A theoretical, mechanism-based concern raised in the scientific literature is that boosting NAD+ metabolism broadly, including in already-abnormal or precancerous cells, could theoretically support the growth of some cancers, since NAD+ metabolism is also important to rapidly dividing cells; this remains a hypothesis discussed in review literature rather than a confirmed clinical risk, and has not been demonstrated as an actual increased cancer risk in the human trials conducted so far. As with any supplement, product quality, purity, and accurate labeled content vary across NMN vendors, since supplement manufacturing does not require the same pre-market efficacy or purity verification as pharmaceutical products.

Regulatory and developmental status

NMN’s regulatory status in the United States changed more than once in recent years. In 2022, the FDA determined that NMN could not be legally marketed as a dietary supplement because it had already been authorized for investigation as a new pharmaceutical drug by a company pursuing an Investigational New Drug (IND) application, which under U.S. law can exclude a substance from the dietary supplement category. This determination was subsequently reversed specifically for beta-NMN, and as of 2025, beta-NMN has been restored to lawful dietary-supplement status in the United States. NMN is not FDA-approved as a drug for any indication; it remains regulated as a supplement ingredient, meaning manufacturers are not required to prove efficacy before sale. Regulatory treatment outside the United States varies by country and was not comprehensively verified for this entry.

Frequently asked questions

What is NMN?

NMN (nicotinamide mononucleotide) is a naturally occurring molecule the body uses as a direct building block to make NAD+, a coenzyme essential for cellular energy production and repair processes that declines with age.

How does NMN work?

It is converted inside cells into NAD+, which fuels energy metabolism and is required for sirtuin proteins and DNA-repair enzymes to function.

What dosage has been studied in human trials?

Human trials have used doses ranging from a single 500 milligram safety dose up to daily amounts in the range of a few hundred milligrams to around 1,250 milligrams per day over several weeks to months, though exact figures vary by study and there is no single agreed clinical dose.

What dosage information circulates online?

NMN vendors and longevity communities commonly recommend roughly 250 to 1,000 milligrams per day, a range that loosely overlaps published trials but is often presented by individual vendors without tracing to a specific study.

Has NMN been studied in humans?

Yes, more so than most longevity compounds discussed on this site. Published randomized human trials have examined safety, insulin sensitivity, exercise performance, and functional walking measures.

Is NMN FDA-approved?

No, it is not approved as a drug for any indication. As of 2025, beta-NMN has lawful dietary-supplement status in the United States after a 2022 FDA determination temporarily excluded it from that category.

What side effects have been reported?

Published trials have generally reported good tolerability at studied doses with no serious short-term adverse events, though long-term safety over years of continuous use has not been established.

What remains unknown?

Whether NMN supplementation extends human lifespan or meaningfully slows biological aging has not been established; the strongest longevity evidence remains in mice. The single most effective human dose, and long-term safety over years of use, also remain undetermined.

Bottom line

NMN sits in an unusual position among longevity compounds: it has a real, published body of human clinical trial evidence, more than many peptides and supplements marketed for the same purpose, showing effects on insulin sensitivity, exercise measures, and functional outcomes in specific study populations. What it does not have is a single confirmed effective human dose, direct evidence that it extends human lifespan (the strongest longevity data remains in mice), or long-term safety data over years of continuous use. Its regulatory status as a U.S. dietary supplement has also fluctuated in recent years, which is itself worth understanding before assessing any product’s claims.